Insight Molecular Diagnostics Inc.
IMDX- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001642380
No open-market purchases or sales by Insight Molecular Diagnostics Inc. insiders were filed in the last 90 days; 40 institutions reported holding it in 13F filings for Q2 2026, worth $108.9M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Insight Molecular Diagnostics Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Of which not filed for Q3 2022 | Q3 2022 | Change |
|---|---|---|---|---|
| Holders | 76 | 1 | 65 | −10 |
| Shares | 68.7M | 15.0K | 66.2M | −2.56M (−3.7%) |
| Value | $61.8M | $13.0K | $48.3M | −$13.5M (−21.9%) |
1 institution that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (5)
Institutions that held Insight Molecular Diagnostics Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jane Street Group, LLC | 30,722 | $22.0K | 0.00% |
| National Asset Management, Inc. | 17,890 | $14.0K | 0.00% |
| Levin Capital Strategies, L.P. | 10,500 | $8.00K | 0.00% |
| Federated Hermes, Inc. | 2,420 | $2.00K | 0.00% |
| China Universal Asset Management Co., Ltd. | 1,111 | $1.00K | 0.00% |
Sold out (15)
Institutions that held Insight Molecular Diagnostics Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Gsa Capital Partners LLP | 160,238 | $144.0K |
| Susquehanna International Group, LLP | 145,804 | $131.0K |
| Cambridge Investment Research Advisors, Inc. | 36,500 | $33.0K |
| Jump Financial, LLC | 29,140 | $26.0K |
| DCF Advisers, LLC | 25,149 | $23.0K |
| Two Sigma Securities, LLC | 21,217 | $19.0K |
| Cinctive Capital Management LP | 19,565 | $18.0K |
| Engineers Gate Manager LP | 17,139 | $15.0K |
| HRT Financial LP | 13,941 | $12.0K |
| FMR LLC | 6,078 | $6.00K |
| Captrust Financial Advisors | 4,503 | $4.00K |
| New York State Common Retirement Fund | 573 | $1.00K |
| Barclays PLC | 41 | $0 |
| Credit Suisse AG | 32 | $0 |
| CoreCap Advisors, LLC | 5 | $0 |
Not filed for Q3 2022 yet (1)
Institutions that held Insight Molecular Diagnostics Inc. at the end of Q2 2022 and haven't filed a 13F for Q3 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| B. Riley Wealth Management, Inc. | 15,000 | $13.0K |